By Priya Raman

Stanford neuroscientist Andrew Huberman will join Hims & Hers’ board as the telehealth company approaches 3 million customers, placing a podcaster with more than 8 million YouTube subscribers at the center of its expansion from hair loss and erectile dysfunction into weight loss, testosterone, preventive care and peptides.

He will formally advise Hims on science and brand marketing and provide separate marketing support through the Huberman Lab podcast. That gives the telehealth company a scientific adviser, a director and a prominent media partner in one arrangement.

One of the internet’s most influential independent health voices becomes a company director. Known for translating science into advice on sleep, fitness, hormones, supplements and longevity, he reaches millions through his podcast and YouTube channel each month. He will owe fiduciary duties—legal obligations to Hims—at a company that can sell treatments he discusses.

What changes when Huberman enters the boardroom?

Huberman’s role differs from his earlier advisory work for fitness and sleep brands. As a director, he will help shape Hims’ strategy firsthand, rather than lend scientific or marketing expertise from outside.

He first contacted CEO Andrew Dudum through a mutual friend, and the two spent six to eight months discussing the future of consumer healthcare. Huberman said the board seat would let him act on shared priorities, including bringing best healthcare practices to the broadest number of people, rather than only describe them.

Dudum framed the same mission around a practical question: how to empower people worldwide to feel better and take more agency in their lives. On a joint call on Monday, both men described making personalized healthcare accessible as their shared ambition.

The board also includes former Netflix CFO David Wells and former DoorDash CFO Kofi Amoo-Gottfried. Huberman adds scientific authority and a large media audience to that group.

Who is the “middle 95%”?

Huberman sees Hims filling the gap between traditional healthcare, where patients can struggle to secure time and attention, and high-end concierge care. He said the “middle 95%” should be able to access personalized care.

That mass-market segment is attracting competition. Hims is not alone in pursuing it: telehealth companies such as Ro and Midi, longevity clinics, testing startups and consumer-health brands all seek to turn once-niche services into mainstream offerings.

Hims enters with nearly 3 million customers, its own pharmacy and manufacturing infrastructure, and a new director whose YouTube subscriber base already exceeds 8 million. The strategic logic is straightforward: convert a mass audience’s interest in optimization into demand for a company that can sell and fulfill treatments while explaining their uses.

Why do peptides raise the stakes?

Hims is pushing into testosterone and peptides, categories that have shifted from niche biohacking, or self-directed health optimization, toward mainstream attention in recent months. Huberman has become a prominent public voice on injectable peptides; Dudum has been building Hims to sell them.

The peptide push predates both Huberman’s appointment and a recent move by the US Health and Human Services Department to make some of the buzziest peptides available by prescription temporarily. Hims signed for a California peptide facility at the end of 2024 and announced the acquisition in February 2025.

By May, Dudum told investors that Hims was following peptide innovation deeply and identified possible uses in pain management, recovery and generalized longevity. The distinction matters: those were potential applications, not guaranteed outcomes.

In recent weeks, Hims previewed Peptides+, a website section intended to offer various peptides once regulatory approval permits, including BPC-157. The planned offering also covers wellness therapies such as NAD+ and vitamin B12. The launch ties scientific claims, regulatory approval and commercial access to one corporate agenda.

Huberman said he has no desire to encourage broad peptide use among people who do not need them, and questioned whether someone without an injury needs BPC or TB-500. One of his biggest reasons for joining was Hims’ plan to control peptide manufacturing from start to finish while leading a discussion about what the products can and cannot do.

He called for the company to serve as a channel for peptide information rather than block it. Dudum likewise said personalized health and longevity require extreme care and caution, an important qualification for a platform that can educate consumers and sell them products.

Can Huberman preserve editorial independence?

The Huberman Lab podcast is regularly among the most popular in its category. Huberman and Dudum said he would remain free to cover the subject broadly, including benefits, risks and uncertainty.

In an interview with Business Insider, Huberman made the central independence pledge: “We will never filter information differently because of a brand relationship.” He also said Hims encouraged him to continue educating audiences independently of any product or platform.

The commercial arrangements are clear. Scicomm Media, Huberman’s media company, will run paid podcast advertisements for Hims & Hers; Huberman will separately advise on science and brand marketing and provide support through his show.

He did not specify how individual podcast episodes, social posts or short clips would disclose the board seat and separate marketing relationship. That leaves a disclosure test unresolved.

Huberman’s thesis is that Hims can give consumers a rigorous route through crowded wellness information and turn them into scientists of themselves. For that thesis to work, the 3 million-customer platform must keep education distinct enough from selling to preserve trust. That separation matters. The board seat makes it harder, not optional.